Inhibition of gastric acid secretion with a mast cell stabiliser, FPL-52694.
1 The effect on gastric acid secretion of a mast cell stabiliser FPL-52694 was examined in nine healthy volunteers. 2 The compound which is moderately well absorbed after oral ingestion, was taken for 5 days prior to the measurement of acid secretion and was also given intravenously during part of the gastric test. A submaximal dose of pentagastrin (0.3 microgram/kg/h) was given by intravenous infusion for 2 h in a controlled test and then after administration of FPL-52694. 3 There was a significant reduction (37%) in acid secretion during the second test which was probably due to the effect of the compound on mast cell degranulation in the gastric mucosa.
D000328:Adult; D002867:Chromones / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D008297:Male; D008407:Mast Cells / Q000187:drug effects*; D008875:Middle Aged; D010418:Pentagastrin
D002867:Chromones; C029061:FPL-52694; D010418:Pentagastrin